Donald "Skip" Trump

May 26, 2015

Donald "Skip" Trump has been named CEO and executive director of the Inova Dwight and Martha Schar Cancer Institute.

Prior to coming to Inova, Trump was CEO and president of Roswell Park Cancer Institute in Buffalo, New York from 2007 to 2014. 

More Like This

Jun 27, 2017

Brian Morra

Brian Morra has been elected executive chairman of Akonni Biosystems' board of directors. In addition to leading the board, Morra will support Akonni Founder and CEO Charles Daitch. He was a senior VP at Pacific-Sierra Research, and was a president at Veridian. 

Jun 22, 2017

Matt Tindall, Martin Reese

Matt Tindall has stepped down as CEO of Fabric Genomics, formerly Omicia, as of early May 2017. He joined the company in March 2016 when he was first appointed to the position. Martin Reese, former CSO and co-founder, has been appointed as the company's CEO. Reese has served as CEO of the company in previous years.

Jun 22, 2017

David Daly

Foundation Medicine has announced that David Daly intends to resign for personal reasons effective August 11. Daly currently serves as chief commercial officer and general manager of clinical oncology solutions for the company. No replacement has yet been named.

Jun 22, 2017

Flemming Ornskov

Waters has appointed Flemming Ornskov to its board of directors. Ornskov currently serves as CEO of Shire, where he also serves as chairman of the executive committee and as a member of its board of directors. He has also held key executive leadership positions at Bayer, Bausch & Lomb, Merck, and Novartis.

Jun 22, 2017

Mara Aspinall

OraSure Technologies has appointed Mara Aspinall to its board of directors. Aspinall currently serves as the president and CEO of Health Catalysts. She also serves as the executive chairman of GenePeeks. Prior to these positions, Aspinall served as president, CEO and global head of Roche Tissue Diagnostics. She also founded and served as CEO and director of On-Q-ity, served as president of Genzyme Genetics, served as president of the Genzyme Pharmaceuticals.

Jun 21, 2017

Philippe Goix

Avant Diagnostics has appointed Philippe Goix as president and CEO. Goix comes to Avant from Prism Health Diagnostics where he served as president, CEO, and co-founder. Before his time at Prism Health, he consulted for several healthcare companies, and has also served as president and CEO of Singulex, and president and CEO of Guava Technologies, now part of Merck Millipore.

Jun 21, 2017

Peter Meintjes

Omixon has appointed Peter Meintjes as CEO. Meintjes replaces current CEO Tim Hague who will step into a consultancy role and remains a shareholder of the company. Most recently, Meintjes served as chief commercial officer at Omixon. He joined the company in 2014.

Jun 16, 2017

Kieran Murphy

GE Healthcare has appointed Kieran Murphy as president and CEO. He succeeds John Flannery, who has been appointed CEO and chairman elect of GE. Murphy was appointed CEO of GE Healthcare Life Sciences in September 2011, and he joined GE Healthcare in 2008 from Whatman. He has also held leadership roles at Mallinckrodt, Novartis, Adprotech, ML Laboratories, and Innovata.

Jun 15, 2017

Robert Green, Natasha Frank

Veritas Genetics has appointed Robert Green and Natasha Frank to its medical and scientific advisory board. Green directs the Genomes2People research program. He also leads the first randomized trials to explore the implementation of medical sequencing in adults and newborns through the MedSeq and BabySeq projects. Frank leads research programs funded by the US National Institutes of Health, Veterans Administration, and the Department of Defense that investigate the biology of stem cells residing in human tissues and their relationship to genetic disease and cancer.

Jun 15, 2017

Sean Freeman

Molecular Assemblies has appointed Sean Freeman to its board of directors. Freeman currently serves as head of strategy and corporate development at NuVasive. He previously served as senior VP of business development for Cole-Parmer Instrument, and as head of corporate ventures and M&A at Life Technologies, which was later acquired by Thermo Fisher Scientific. He has also worked as an investment banker in Merrill Lynch's mergers & acquisitions group.

Jun 07, 2017

Heikki Lanckriet, Pilar de la Huerta, Peter Llewellyn-Davis

Sygnis has announced changes to its management team and supervisory board. Former Co-CEO Heikki Lanckriet will become sole CEO of the company and will also retain his role as CSO. Additionally, supervisory board members Maria-Hesús Sabatés Mas and Franz Wilhelm Hopp will be ending their appointment terms and will not be up for re-election. Pilar de la Huerta and Peter Llewellyn-Davis will be nominated to replace them. De la Huerta will also resign from her position as member of the management board. Llewellyn-Davis currently serves as non-executive director and chairman of the audit committee of Shield Therapeutics. He previously served as CFO and chief business officer of MediGene.

Jun 05, 2017

Joris Veltman

Joris Veltman has taken the position of director of the Institute of Genetic Medicine at Newcastle University in the UK. He previously served as a professor of translational genomics in the department of human genetics at Radboud University Medical Centre in Nijmegen in the Netherlands, with a joint appointment in the department of clinical genetics at Maastricht University Medical Centre.

Jun 02, 2017

Howard McLeod

Viviphi has appointed Howard McLeod to its precision medicine advisory board, and has named him senior research advisor in precision medicine. McLeod previously served in leadership positions at the H. Lee Moffitt Cancer Center's Department of Individualized Cancer Management. He also served as an endowed research chair in the state of Florida, professor at the University of South Florida, and serves as a 1000 Talent Scholar in China. Additionally, he has served on the FDA's committee on clinical pharmacology and on the National Institutes of Health's Human Genome Advisory Council.

Jun 01, 2017

Shelly Guyer

Invitae has appointed Shelly Guyer as its CFO, effective June 12. She will also serve as the company's principal financial officer. Invitae's current CFO Lee Bendekgey will fully transition to his new role as COO. Most recently, Guyer served as CFO of Veracyte. 

May 31, 2017

Mona Miller

The American Society of Human Genetics has appointed Mona Miller as executive director. She will be responsible for representing the ASHG on a day-to-day basis, for guiding and implementing its broad agenda in consultation with the president and board, and for interacting on an ongoing basis with society committees. Miller currently serves as the deputy executive director for programs and finance at the Society for Neuroscience. She has previously served as the society's senior director of communications and public affairs, the senior officer of public affairs at the Pew Charitable Trusts, and as communications director to former Senator Barbara Mikulski.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.